- Home
- PETS vs DXR Comparison
PETS vs DXR Comparison
Compare PETS & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- DXR
- Stock Information
- Founded
- PETS 1996
- DXR 1970
- Country
- PETS United States
- DXR United States
- Employees
- PETS N/A
- DXR N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- DXR Medical/Dental Instruments
- Sector
- PETS Consumer Staples
- DXR Health Care
- Exchange
- PETS Nasdaq
- DXR Nasdaq
- Market Cap
- PETS 50.0M
- DXR 46.9M
- IPO Year
- PETS N/A
- DXR N/A
- Fundamental
- Price
- PETS $2.62
- DXR $13.49
- Analyst Decision
- PETS Sell
- DXR Strong Buy
- Analyst Count
- PETS 1
- DXR 1
- Target Price
- PETS $3.20
- DXR $25.00
- AVG Volume (30 Days)
- PETS 90.5K
- DXR 6.2K
- Earning Date
- PETS 10-14-2025
- DXR 01-01-0001
- Dividend Yield
- PETS N/A
- DXR N/A
- EPS Growth
- PETS N/A
- DXR 3.46
- EPS
- PETS N/A
- DXR 0.36
- Revenue
- PETS $226,972,000.00
- DXR $66,306.00
- Revenue This Year
- PETS N/A
- DXR N/A
- Revenue Next Year
- PETS $2.98
- DXR N/A
- P/E Ratio
- PETS N/A
- DXR $36.83
- Revenue Growth
- PETS N/A
- DXR N/A
- 52 Week Low
- PETS $2.42
- DXR $6.55
- 52 Week High
- PETS $6.85
- DXR $14.00
- Technical
- Relative Strength Index (RSI)
- PETS 50.52
- DXR 62.80
- Support Level
- PETS $2.46
- DXR $12.52
- Resistance Level
- PETS $2.68
- DXR $13.10
- Average True Range (ATR)
- PETS 0.11
- DXR 0.30
- MACD
- PETS 0.02
- DXR -0.07
- Stochastic Oscillator
- PETS 84.31
- DXR 65.34
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.